Qian Subo, Zhang Shun, Xia Weimin, Xu Ding, Qi Jun, Shen Haibo, Wu Yu
Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Prostate. 2021 Jun;81(8):478-486. doi: 10.1002/pros.24128. Epub 2021 Apr 16.
Our study aimed to investigate the correlation of prostatic morphological parameters and benign prostatic hyperplasia (BPH) clinical progression in aging Chinese men.
In this retrospective study, a total of 1038 patients were reviewed. Prostatic morphology was measured by transrectal ultrasound (TRUS). Detailed medical history of all candidates was recorded and analyzed after being classified by specific prostatic measurements. Univariate and multivariate logistic regression analyses were used to estimate the correlation between variables.
The cumulative incidence of BPH clinical progression was 63.68% (661/1038) in the study population. Prostate volume (PV), transitional zone volume (TZV), transitional zone index (TZI), and intravesical prostatic protrusion (IPP) were all positively associated with BPH progression (all p < .001). Patients with a PV > 60 ml, TZV > 15 ml, TZI > 0.5, or IPP > 5 mm had a significantly higher possibility of overall BPH clinical progression (adjusted odds ratio (OR): 2.485, 1.678, 1.886, and 1.924, respectively; 95% confidence interval (CI): 1.559-3.960, 1.131-2.489, 1.379-2.579, and 1.357-2.728, correspondingly).
Prostatic morphological parameters are significantly associated with BPH clinical progression. Patients with larger prostatic morphological parameters are more easily prone to clinical progress. As a result, reasonable managements should be timely considered for those patients before clinical progression occurs.
本研究旨在探讨老年中国男性前列腺形态学参数与良性前列腺增生(BPH)临床进展的相关性。
在这项回顾性研究中,共纳入1038例患者进行分析。经直肠超声(TRUS)测量前列腺形态。记录所有受试者的详细病史,并根据特定的前列腺测量值进行分类后分析。采用单因素和多因素逻辑回归分析评估变量之间的相关性。
研究人群中BPH临床进展的累积发生率为63.68%(661/1038)。前列腺体积(PV)、移行区体积(TZV)、移行区指数(TZI)和膀胱内前列腺突出(IPP)均与BPH进展呈正相关(均p < 0.001)。PV > 60 ml、TZV > 15 ml、TZI > 0.5或IPP > 5 mm的患者发生BPH总体临床进展的可能性显著更高(调整后的优势比(OR)分别为:2.485、1.678、1.886和1.924;95%置信区间(CI)相应为:1.559 - 3.960、1.131 - 2.489、1.379 - 2.579和1.357 - 2.728)。
前列腺形态学参数与BPH临床进展显著相关。前列腺形态学参数较大的患者更容易出现临床进展。因此,对于这些患者,应在临床进展发生前及时考虑合理的管理措施。